On the Alexion and Synageva deal

The Wall Street Journal did a nice job covering Alexion's takeover of Synageva.  Here's what I've taken away from this deal.

• ALXN's CEO is on his second month on the job. 
• This is the 4th highest premium ever paid in a corporate takeover via Dealogic 

chart via @WSJ & Dealogic

• He's trying to follow the playbook of paying up for a high potential drug.
• The lead drug in Syngeva's pipeline hasn't been approved in the U.S.
• The timing stinks as years of extremely high drug prices are coming under more and more scrutiny by legislators

The new guy has balls.  Time will tell if it'll pay off